KR900700130A - 종양전이의 면역요법용, 바이러스 변성 종양 백신과 그의 제조방법 - Google Patents

종양전이의 면역요법용, 바이러스 변성 종양 백신과 그의 제조방법

Info

Publication number
KR900700130A
KR900700130A KR1019890702004A KR890702004A KR900700130A KR 900700130 A KR900700130 A KR 900700130A KR 1019890702004 A KR1019890702004 A KR 1019890702004A KR 890702004 A KR890702004 A KR 890702004A KR 900700130 A KR900700130 A KR 900700130A
Authority
KR
South Korea
Prior art keywords
vaccine
tumor
virus
immunotherapy
state
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019890702004A
Other languages
English (en)
Korean (ko)
Inventor
쉬르마춰 볼커
Original Assignee
에이치.씨.에이치. 주르 하우젠 알.그룬발트
도이취스 크렙스포르슝스젠트룸
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6348527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900700130(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에이치.씨.에이치. 주르 하우젠 알.그룬발트, 도이취스 크렙스포르슝스젠트룸 filed Critical 에이치.씨.에이치. 주르 하우젠 알.그룬발트
Publication of KR900700130A publication Critical patent/KR900700130A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1019890702004A 1988-03-01 1989-02-27 종양전이의 면역요법용, 바이러스 변성 종양 백신과 그의 제조방법 Withdrawn KR900700130A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3806565A DE3806565A1 (de) 1988-03-01 1988-03-01 Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
DEP3806565.7 1988-03-01
PCT/EP1989/000186 WO1989007946A1 (fr) 1988-03-01 1989-02-27 Vaccins tumoraux modifies viralement pour immunotherapie de metastases tumorales

Publications (1)

Publication Number Publication Date
KR900700130A true KR900700130A (ko) 1990-08-11

Family

ID=6348527

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890702004A Withdrawn KR900700130A (ko) 1988-03-01 1989-02-27 종양전이의 면역요법용, 바이러스 변성 종양 백신과 그의 제조방법

Country Status (10)

Country Link
US (1) US5273745A (https=)
EP (1) EP0331102B1 (https=)
JP (1) JPH02504034A (https=)
KR (1) KR900700130A (https=)
AT (1) ATE90877T1 (https=)
AU (1) AU3188989A (https=)
DE (2) DE3806565A1 (https=)
DK (1) DK541889A (https=)
ES (1) ES2042828T3 (https=)
WO (1) WO1989007946A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922444A1 (de) * 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
DE4204132C2 (de) * 1991-02-12 1997-12-18 Rudolf Dr Pekar Aufbereitung für die Gewinnung von Vakzinen für eine Immuntherapie
EP1216710B1 (en) * 1991-10-04 2006-04-05 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
EP2009119A1 (en) 1993-04-30 2008-12-31 Wellstat Biologics Corporation Compositions for treating cancer using viruses
DE19506483A1 (de) * 1995-02-24 1996-08-29 Jens Dr Dr Atzpodien Lyophilisat-Vakzine
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
EP0805207A1 (en) * 1996-05-02 1997-11-05 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression plasmid for tumor rejection
DE69723580T2 (de) * 1996-05-03 2004-06-03 Thomas Jefferson University Impfstoff gegen metastasierenden kolorektalkrebs.
WO1998014206A1 (en) * 1996-10-04 1998-04-09 Thomas Jefferson University T cells mediating an immune response and methods of use
DE69731950T2 (de) * 1997-08-22 2005-05-19 Science Park Raf S.P.A. Tumorvakzinierung mittels Verwendung autologer oder HLA-verwandter Antigen präsentierender Zellen (APC), die mit einem Tumorantigen sowie einem eine Immunantwort hervorrufenden Fremdantigen transduziert sind
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
JP2003530301A (ja) * 1999-04-15 2003-10-14 ウェルスタット バイオロジクス コーポレイション ウイルスを用いた新生物の処置
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
EP1092439A1 (en) * 1999-10-13 2001-04-18 Thorsten Dr. Ahlert Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
RU2172182C1 (ru) * 2000-07-27 2001-08-20 Бритов Василий Александрович Способ профилактики и лечения заболеваний иммунной системы и средство для его осуществления
KR20040094635A (ko) * 2003-05-02 2004-11-10 주식회사 엠디바이오알파 항종양 활성의 유도를 위한 종양 백신의 제조방법 및그것을 함유하고 있는 약제 조성물
KR101492643B1 (ko) 2005-12-02 2015-02-12 이칸 스쿨 오브 메디슨 엣 마운트 시나이 비-천연 표면 단백질을 제시하는 키메라 바이러스 및 그의용도
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
ES2380289T3 (es) 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer
EA038981B1 (ru) 2013-03-14 2021-11-17 Икан Скул Оф Медсин Эт Маунт Синай Вирусы болезни ньюкасла и их применение
WO2015127501A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2918927A1 (de) * 1979-05-10 1980-11-20 Hans Prof Dr Limburg Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung
DE3432714A1 (de) * 1984-09-06 1986-04-24 Behringwerke Ag, 3550 Marburg Tumortherapeutikum und verfahren zu seiner herstellung
HU197517B (en) * 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection

Also Published As

Publication number Publication date
DK541889D0 (da) 1989-10-31
EP0331102B1 (de) 1993-06-23
DE58904760D1 (de) 1993-07-29
US5273745A (en) 1993-12-28
DK541889A (da) 1989-10-31
AU3188989A (en) 1989-09-22
EP0331102A1 (de) 1989-09-06
JPH02504034A (ja) 1990-11-22
ATE90877T1 (de) 1993-07-15
DE3806565C2 (https=) 1991-04-25
DE3806565A1 (de) 1989-09-14
ES2042828T3 (es) 1993-12-16
WO1989007946A1 (fr) 1989-09-08

Similar Documents

Publication Publication Date Title
KR900700130A (ko) 종양전이의 면역요법용, 바이러스 변성 종양 백신과 그의 제조방법
ATE203421T1 (de) Keime von kobalt-palladium zur thermischen behandlung von tumoren
ES2177964T3 (es) Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.
FI930206A0 (fi) Adoptiv immunoterapi med interleukin-7
PT1526172E (pt) Processo para a replicação de vírus influenza em cultura celular e os vírus influenza que podem ser obtidos pelo processo
DK0781092T3 (da) Nucleinsyre som koder for adenovirus E1A-polypeptid til sensibilisering af tumorceller for kemoterapi eller bestråling
ATE120372T1 (de) Antikörper für die antilymphozyten- antikörpertherapie.
Pollard et al. Radiation action on DNA in bacteria: Effect of oxygen
ATE90568T1 (de) Verwendung von zink- oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen.
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
GB1508878A (en) Hepatitis a antigen
ES8800725A1 (es) Un procedimiento para producir un anticuerpo monoclonal
AR015237A1 (es) Una composicion de membranas celulares tumorales modificadas con hapteno, metodo para obtenerlas y su uso.
ATE322540T1 (de) Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender
Kampschmidt et al. Plasma enzymes in tumor-bearing rats
PH23658A (en) Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor
ES550089A0 (es) Procedimiento para producir una vacuna coadyuvada que contiene un antigeno seleccionado de proteinas, bacterias y virus.
ES2047946T3 (es) Metodos de cultivos celulares para producir proteina c activada.
ATE336588T1 (de) In-vitro verpackung von adeno-assozierten virus dns
FR2150799A1 (en) Equine infectious anaemia - prepn of immunising vaccine
SU640725A1 (ru) Способ получени искусственных костных трансплантатов
SU611620A1 (ru) Способ обезболивани при переломах костей
TW221711B (en) N-AFP monoclonal antibody and method of preparation thereof
Butow Facial cleft deformities: Surgical and non-surgical aspects.
FR2059561A1 (en) Anti aphthic vaccine

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19891031

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid